WP903

WP903 is a synthetic anthracycline analog and a derivative of doxorubicin, specifically a 4-demethoxy 2'-halogenated (iodo) analog with altered basicity at the 3'-position. Developed by Waldemar Priebe at the MD Anderson Cancer Center, WP903 was designed to circumvent multidrug resistance (MDR) mechanisms and potentially reduce the cardiotoxicity typically associated with traditional anthracycline therapy. It acts as a topoisomerase II poison, stabilizing the cleavable complex and leading to double-strand DNA breaks, which subsequently triggers apoptosis. Preclinical studies have evaluated its efficacy in melanoma cell lines, including those resistant to doxorubicin, demonstrating its potential as a cytotoxic agent against resistant tumor phenotypes.

Other names

4-demethoxy-2'-iodo-3'-hydroxy-doxorubicin2'-iodo-4-demethoxy-3'-hydroxy-doxorubicin